On October 13, 2022 Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, reported that the Company will present preclinical data on TYRA-200 during a poster session at the 34th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain (Press release, Tyra Biosciences, OCT 13, 2022, View Source [SID1234622013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: TYRA-200: Potent Against FGFR2 Fusions, Molecular Brake Mutations and Gatekeeper Resistance
Date/Time/Location: Wednesday, October 26, 2022, 12-20:00 CET, Exhibition Hall
Session/Session Code: Molecular Targeted Agents 1, PP20
Poster #: 47

Regular abstracts are available on the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) website. The poster on TYRA-200 will be made available on the TYRA website under the "For Investors" section on October 26, 2022.